Paper36911798
The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases.
Choi H and 2 others. Immune Netw, 2023. Cited by 10 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases. Papers, record 36911798. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36911798
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References97
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18,219,309 | Shaping and reshaping CD8+ T-cell memory. | Nat Rev Immunol | 2008 | https://conductscience.org/library/papers/18219309 | PubMed |
| 2 | 17,114,451 | Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. | J Immunol | 2006 | https://conductscience.org/library/papers/17114451 | PubMed |
| 3 | 33,262,762 | Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33262762 | PubMed |
| 4 | 30,100,906 | Targeting Resident Memory T Cells for Cancer Immunotherapy. | Front Immunol | 2018 | https://conductscience.org/library/papers/30100906 | PubMed |
| 5 | 15,980,149 | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15980149 | PubMed |
| 6 | 22,262,649 | Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. | J Gene Med | 2012 | https://conductscience.org/library/papers/22262649 | PubMed |
| 7 | 28,219,080 | Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. | Nature | 2017 | https://conductscience.org/library/papers/28219080 | PubMed |
| 8 | 19,540,806 | Aging in the lympho-hematopoietic stem cell compartment. | Trends Immunol | 2009 | https://conductscience.org/library/papers/19540806 | PubMed |
| 9 | 8,600,537 | Immunological memory and protective immunity: understanding their relation. | Science | 1996 | https://conductscience.org/library/papers/8600537 | PubMed |
| 10 | 21,739,672 | T cell exhaustion. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21739672 | PubMed |
| 11 | 35,489,446 | Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35489446 | PubMed |
| 12 | 12,242,449 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. | Science | 2002 | https://conductscience.org/library/papers/12242449 | PubMed |
| 13 | 15,240,677 | IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. | J Immunol | 2004 | https://conductscience.org/library/papers/15240677 | PubMed |
| 14 | 33,824,268 | CAR-T cell therapy: current limitations and potential strategies. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33824268 | PubMed |
| 15 | 16,818,744 | Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. | J Immunol | 2006 | https://conductscience.org/library/papers/16818744 | PubMed |
| 16 | 28,591,633 | Cytochrome c Oxidase Activity Is a Metabolic Checkpoint that Regulates Cell Fate Decisions During T Cell Activation and Differentiation. | Cell Metab | 2017 | https://conductscience.org/library/papers/28591633 | PubMed |
| 17 | 32,756,549 | SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. | Nature | 2020 | https://conductscience.org/library/papers/32756549 | PubMed |
| 18 | 34,604,060 | Immunotherapeutic Potential of T Memory Stem Cells. | Front Oncol | 2021 | https://conductscience.org/library/papers/34604060 | PubMed |
| 19 | 28,994,018 | Memory CD4+ T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells. | Cell Oncol (Dordr) | 2018 | https://conductscience.org/library/papers/28994018 | PubMed |
| 20 | 35,194,180 | Regulation of tissue-resident memory T cells by the Microbiota. | Mucosal Immunol | 2022 | https://conductscience.org/library/papers/35194180 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,983,431 | M1 macrophage-derived fusogenic nanovesicles co-loaded with Fe3O4/IR780 suppress osteosarcoma via a sonodynamic-ferroptosis-immune triad. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42983431 | PubMed |
| 41,462,958 | Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462958 | PubMed |
| 41,438,430 | Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41438430 | PubMed |
| 40,762,187 | Inverse Regulation of TLR4 and PD-L1 Shapes the Inflammatory Tumor Microenvironment in Oral Squamous Cell Carcinomas. | J Oral Pathol Med | 2025 | https://conductscience.org/library/papers/40762187 | PubMed |
| 40,078,788 | Metabolic Signaling as a Driver of T Cell Aging. | Immune Netw | 2025 | https://conductscience.org/library/papers/40078788 | PubMed |
| 39,776,798 | Ex vivo enhancement of CD8+ T cell activity using functionalized hydrogel encapsulating tonsil-derived lymphatic endothelial cells. | Theranostics | 2025 | https://conductscience.org/library/papers/39776798 | PubMed |
| 39,754,657 | APOM Modulates the Glycolysis Process in Liver Cancer Cells by Controlling the Expression and Activity of HK2 via the Notch Pathway. | Biochem Genet | 2026 | https://conductscience.org/library/papers/39754657 | PubMed |
| 39,035,733 | Hypothesis: hematogenous metastatic cancer cells of solid tumors may disguise themselves as memory macrophages for metastasis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39035733 | PubMed |
| 37,907,738 | CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37907738 | PubMed |
| 37,511,431 | T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511431 | PubMed |
| 36,911,804 | Back to the T Cell: Basic and Clinical Application. | Immune Netw | 2023 | https://conductscience.org/library/papers/36911804 | PubMed |
Genes45
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36911798
GET https://conductscience.org/api/papers/v1/36911798/references?page=2